Safety and efficacy of eflapegrastim in reducing severe neutropenia in patients treated with myelosuppressive chemotherapy in a phase 3 randomized controlled trial compared to pegfilgrastim (ADVANCE trial)

Authors :: Julio Antonio Peguero
Richy Agajanian
Zandong Yang
Patrick Wayne Cobb
Inderjit Mehmi
Osama Hlalah
Alvaro Restrepo
Lee S. Schwartzberg
Jayaram S. Bharadwaj
Gajanan Bhat
Source :: Journal of Clinical Oncology. 36:e12513-e12513
Publication Year :: 2018
Publisher :: American Society of Clinical Oncology (ASCO), 2018.
Abstract: e12513Background: Eflapegrastim is a novel investigational biologic comprised of recombinant human G-CSF covalently linked to the human immunoglobulin G4FC fragment using proprietary LAPSCOVERY™ te...

Full Text Access

Tools